نتایج جستجو برای: dolutegravir
تعداد نتایج: 953 فیلتر نتایج به سال:
BACKGROUND The results of several clinical trials suggest that the integrase inhibitor dolutegravir may be less prone than other drugs to the emergence of HIV drug resistance mutations in treatment-naive patients. We have shown that the R263K mutation commonly emerged during tissue culture selection studies with dolutegravir and conferred low levels of resistance to this drug while simultaneous...
Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized by uridine diphosphate glucuronosyl transferase 1A1; no inhibition or induction of cytochrome P4...
BACKGROUND Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance. METHODS ING111762 (SAILING) is a 48 week, phase 3, randomised, double-blind, ac...
RATIONALE The integrase inhibitor dolutegravir is now recommended as first-line treatment for HIV. A single case of myocarditis after treatment with dolutegravir was reported in the FLAMINGO trial. We present here 2 cases of severe myocarditis that occurred shortly after the initiation of dolutegravir treatment. PATIENTS CONCERNS The first case is a 45-year-old female who developed severe con...
OBJECTIVES Dolutegravir is a second-generation integrase strand transfer inhibitor (InSTI) that has been recently approved by the FDA to treat antiretroviral therapy-naive as well as treatment-experienced HIV-infected individuals, including those already exposed to the first-generation InSTI. Despite having a different mutational profile, some cross-resistance mutations may influence its suscep...
Dolutegravir is neither an inducer nor inhibitor of metabolising enzymes, and it therefore has a low propensity to act as perpetrator drug-drug interactions. Clinically significant decreases in dolutegravir exposure occur when co-administered with strong inducers (e.g. rifampicin, efavirenz) drug enzymes efflux transporters for which substrate – this can be overcome by increasing the dose from ...
BACKGROUND AND OBJECTIVES Long-term use of antiretroviral therapy (ART) to treat HIV infection has been associated with dyslipidemia and metabolic and cardiovascular complications. Available options for patients at risk of cardiovascular disease include antiretroviral drugs with improved lipid profiles. Dolutegravir is one of a new generation of HIV integrase inhibitors recently incorporated in...
impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. renal failure after initiation of tenofovir disoproxil fumarate. et al. Tenofovir-related nephrotoxicity in human immunodefi-ciency virus-infected patients: three cases of ...
Of all the antiretroviral therapy (ART) drugs in recent development, few have generated as much expectation as the HIV integrase strand transfer inhibitor dolutegravir. Raltegravir, the fi rst in this class, has proved to be a very valuable drug, from treatment initiation to late salvage. However, in an era in which once daily therapy and single tablet regimens dominate the treatment initiation...
BACKGROUND In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. METHODS SPRING-2 is an ongoing phase 3, randomised, double-blind, active-controlled, non-inferiority study in treatment-naive adults infected with HI...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید